Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06840470 · ClinicalTrials.gov registry record · Phase 4
Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
A Phase 4 study of Sebaceous Hyperplasia, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06840470 is a Phase 4 study of Sebaceous Hyperplasia that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06840470, a Phase 4 study of Sebaceous Hyperplasia, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.
Conditions Studied
Interventions
- DRUG Imiquimod 5% Topical Cream
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2027-09-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06840470
The ClinicalTrials.gov registry entry for NCT06840470 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sebaceous Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Imiquimod 5% Topical Cream is the first listed.
NCT06840470 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06840470 about?
NCT06840470 is a clinical study titled "Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia". This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.
What is the current status of trial NCT06840470?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-03-11. Estimated completion is 2027-09-11.
What conditions does trial NCT06840470 study?
This clinical trial studies the following conditions: Sebaceous Hyperplasia.
What interventions are being tested in trial NCT06840470?
The interventions under investigation include: Imiquimod 5% Topical Cream (DRUG).
Who is sponsoring clinical trial NCT06840470?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06840470 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.